AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 91 min read$BLTE

Lin Yu-Hsin sold $19.1M of BLTE

Lin Yu-Hsin (Chief Executive Officer) sold 100,435 shares of BELITE BIO, INC (BLTE) at an average of $190.00 ($180.29–$198.09, $19.08M total) across 19 trades over 2026-09-04 to 2026-09-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lin Yu-Hsin
Published Sep 9, 2026, 11:39 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 12:04 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BLTE
Bearish
medium confidence
Mentioned
$BLTE
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLTEBearishMed
01

Why it matters

The disclosed sale adds supply pressure and may influence short‑term price action.

02

Market read

Primary insider sell for a micro‑cap biotech; relevant for traders monitoring insider activity and biotech sector sentiment.

03

What to watch

Potential upcoming financing round or clinical trial news could offset sell pressure.

Relevance 6/10Novelty 7/10Timing: filing today

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$BLTEBearishMedium confidence
Context

CEO Lin Yu-Hsin sold 100,435 shares for $19.1M via a 10b5‑1 plan, reducing his stake to 70,134 shares.

Expected impact

Potential modest decline of 2‑4% over the next few days as the market digests the sale.

Evidence & confidence

The sale size is material for a micro‑cap biotech and was executed through a pre‑arranged plan, suggesting a planned liquidity event rather than panic, but still adds supply pressure.

Market effects

Sector

May raise scrutiny on biotech insider activity, prompting investors to watch other micro‑cap biotech insiders.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Low global relevance beyond niche biotech community.

Counterpoint

What could challenge this read

The 10b5‑1 plan indicates a routine liquidity event; the sale may not reflect negative fundamentals.

Key entities

  • person
    Lin Yu-Hsin

    Chief Executive Officer of Belite Bio, Inc.

  • company
    Belite Bio, Inc.

    Biotech firm focused on gene‑editing therapies.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BLTE insider trading history →

Related articles

SEP 4
$BLTEMedAI 8/10

Belite Bio (BLTE) Is Up 9.0% After FDA Grants Priority Review To Tinlarebant Stargardt NDA

Belite Bio (BLTE) shares rose 9.0% after the FDA granted priority review to its new drug application for tinlarebant, a treatment for Stargardt disease. The company expects a decision by February 12, 2027, and is preparing for commercial launch, targeting 53,000 patients. Phase III data showed a 35.7% reduction in lesion growth versus placebo. The company projects $563.2 million revenue and $318.3 million earnings by 2029, a 24% upside to its current price.

simplywall.st3 min
AUG 12
$BLTEMedAI 8/10

BLTE Stock Rises as FDA Grants Priority Review to Tinlarebant NDA

Belite Bio (BLTE) said the FDA accepted its tinlarebant NDA for Stargardt disease type I and granted priority review. A decision is expected Feb. 12, 2027. Priority review targets action in six months. The filing is based on Phase III DRAGON results showing a 35.7% reduction in atrophic lesion growth rate vs placebo. BLTE shares rose about 6.2% on Tuesday.

tradingview.com4 min
AUG 12
$BLTEMedAI 8/10

Belite Bio lands priority review for first Stargardt treatment

The FDA accepted and granted priority review to Belite Bio’s (Nasdaq: BLTE) New Drug Application for tinlarebant to treat Stargardt disease type 1. The Prescription Drug User Fee Act target action date is Feb. 12, 2027. The program previously received breakthrough therapy, fast track, and rare pediatric designations, and has orphan drug status in multiple regions.

thepharmaletter.com4 min
JUL 20
$BLTEMedAI 8/10

Why Is Belite Bio Stock Gaining Monday? - Belite Bio (NASDAQ:BLTE)

Belite Bio (NASDAQ:BLTE) reported additional secondary endpoint statistics from its Phase 3 DRAGON trial of tinlarebant for Stargardt disease type 1. The company said qAF stayed stable or fell about 2% at 25 months with tinlarebant versus about a 20% increase with placebo, and the trial previously met its primary endpoint, reducing retinal lesion growth by 35.7% versus placebo. BLTE shares rose about 3.11% to $154.74.

benzinga.com4 min